Lexicon Pharmaceuticals Inc.
LXRX | NASDAQ
$2.07
+$0.03 (+1.47%)
Sep 22, 2026, 10:49 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 49.8M | 31.08M | 1.2M | 139K | 298K | 24M |
Cost of Revenue | 274K | 616K | 58.97M | 52.52M | 55.05M | 1.93M |
Gross Profit | 49.53M | 30.47M | -57.77M | -52.38M | -54.75M | 22.07M |
Operating Income | -48.91M | -197.12M | -171.75M | -100.76M | -87.09M | -47.8M |
Interest Income | 6.91M | 12.29M | 7.73M | 1.6M | 134K | 2.77M |
Pretax Income | -50.34M | -200.4M | -177.12M | -101.94M | -87.76M | -58.57M |
Net Income | -50.34M | -200.4M | -177.12M | -101.94M | -87.76M | -58.57M |
Selling & General & Admin | 37.32M | 131.9M | n/a | n/a | n/a | 47.23M |
Research & Development | 61.12M | 84.48M | 58.89M | 52.82M | 55.05M | 153.62M |
Other Expenses | n/a | 11.2M | 55.1M | -4.43M | -22.7M | -130.99M |
Operating Expenses | 98.44M | 227.58M | 113.98M | 48.38M | 32.34M | 69.87M |
Interest Expense | 8.34M | 15.58M | 13.1M | 2.78M | 802K | 14.54M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 98.71M | 228.2M | 172.95M | 100.9M | 87.39M | 71.8M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 363.05M | 320.03M | 221.13M | 165.73M | 145.65M | 110.84M |
Shares Outstanding (Diluted) | 363.05M | 320.03M | 221.13M | 165.73M | 145.65M | 110.84M |
EPS (Basic) | -0.14 | -0.63 | -0.80 | -0.62 | -0.61 | -0.63 |
EPS (Diluted) | -0.14 | -0.63 | -0.80 | -0.62 | -0.61 | -0.63 |
EBITDA | -41.38M | -184.29M | -169.76M | -100.03M | -86.66M | -41.1M |
EBIT | -42M | -184.82M | -170.31M | -100.46M | -86.96M | -44.03M |
Depreciation & Amortization | 621K | 534K | 554K | 427K | 292K | 2.93M |
Add to Watchlist
Select watchlists to add or remove LXRX